Patents by Inventor Thor WAGNER

Thor WAGNER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CHIMERIC ANTIGEN RECEPTORS (CARS) TARGETING NATURAL KILLER CELLS
    Publication number: 20230348854
    Abstract: The current disclosure provides chimeric antigen receptors (CARs) that bind a natural killer (NK) cell surface marker, resulting in destruction of the bound NK cell. The NK cell surface markers include an activating NK cell receptor, and an inhibitory NK cell receptor. Cells that are genetically modified to express these CARs and uses of the CAR modified cells are also described.
    Type: Application
    Filed: May 7, 2021
    Publication date: November 2, 2023
    Applicant: Seattle Children's Hospital d/b/a Seattle Children's Research Institute
    Inventors: Thor Wagner, Floriane Ngako Kameni
  • METHODS AND COMPOSITIONS FOR ENGINEERING CD4-DEFICIENT CAR T CELLS AND ANTI-CD4 CAR T CELLS AND USES THEREOF
    Publication number: 20220054549
    Abstract: Some aspects of the methods and compositions provided herein relate to the disruption of at least one CD4 gene in a cell, such as a CD4+ T cell. In some embodiments, the disruption comprises use of a CRISPR guide polynucleotide. Some embodiments also include the preparation and use of a cell having at least one disrupted CD4 gene and a chimeric antigen receptor (CAR). Some aspects of the methods and compositions provided herein relate to CARs, such as an anti-CD4 CAR or an anti-CD19 CAR, and use to treat disorders including HIV, acute myeloid leukemia (AML), and acute lymphocytic leukemia (ALL).
    Type: Application
    Filed: March 17, 2020
    Publication date: February 24, 2022
    Inventors: Thor Wagner, Jaya Sahni
  • CCR5 disruption of cells expressing anti-HIV chimeric antigen receptor (CAR) derived from broadly neutralizing antibodies
    Patent number: 10494422
    Abstract: The present application generally relates to methods of genetically modifying a T-cell comprising a chimeric antigen receptor wherein the T-cell lacks a co-receptor for HIV. The application further relates to methods of making a nucleic acid encoding a chimeric antigen receptor, nucleic acids encoding a chimeric antigen receptor, and genetically modified T-cells comprising a chimeric antigen receptor disclosed herein. The application further relates to methods of treating, inhibiting, or ameliorating HIV in a subject including administering to the subject a cell disclosed herein.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: December 3, 2019
    Assignee: Seattle Children's Hospital
    Inventors: Thor Wagner, Andrew M. Scharenberg, David J. Rawlings, Blythe Sather, Jaya Sahni
  • CCR5 DISRUPTION OF CELLS EXPRESSING ANTI-HIV CHIMERIC ANTIGEN RECEPTOR (CAR) DERIVED FROM BROADLY NEUTRALIZING ANTIBODIES
    Publication number: 20170044240
    Abstract: The present application generally relates to methods of genetically modifying a T-cell comprising a chimeric antigen receptor wherein the T-cell lacks a co-receptor for HIV. The application further relates to methods of making a nucleic acid encoding a chimeric antigen receptor, nucleic acids encoding a chimeric antigen receptor, and genetically modified T-cells comprising a chimeric antigen receptor disclosed herein. The application further relates to methods of treating, inhibiting, or ameliorating HIV in a subject including administering to the subject a cell disclosed herein.
    Type: Application
    Filed: April 8, 2015
    Publication date: February 16, 2017
    Inventors: Thor WAGNER, Andrew M. SCHARENBERG, David J. RAWLINGS, Blythe SATHER, Jaya SAHNI